IASLC-ACLC, Guangzhou, China, 08-10 November 2018

Afatinib followed by osimertinib in real-world patients with EGFR mutation-positive NSCLC: an observational study

Maximilian J. Hochmair, Alessandro Morabito, Desiree Hao, Cheng-Ta Yang, Ross A. Soo, James C-H Yang, Rasim Gucalp, Balazs Halmos, Lara Wang, Amanda Golembesky, Angela Märten, Tanja Cufer


Learn more about the science behind this poster in the videos, papers and other materials below.

Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors

V. Hirsh. Ther Adv Med Oncol. 10(1), 1758834017753338 (2018)

Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer

T. S. Mok, Y. L. Wu, M. J. Ahn, et al. N Engl J Med. 376(7), 629-640 (2017)


In the European Union, afatinib is approved for use in TKI-naive adults with locally advanced or metastatic NSCLC with activating EGFR mutations and in patients with NSCLC of squamous histology on or after chemotherapy. It is not yet approved in other indications.